Skip to Main Content

Paper Details

Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Sci Transl Med
11
2022
-A2, 1i, AML, AML cells, HLA, HLA-A2, T cell receptor, T cells, T controlled solid tumor lines, TCR, TCR (T), WT1, WT1 (T, WT1 protein, WT1-expressing solid tumor lines, Wilms, Wilms' tumor, Wilms' tumor antigen 1, Wilms' tumor antigen 1 peptide, acute myeloid leukemia, antileukemic, engineered T, engineered T cells, human leukocyte antigen A*02, immunoproteasome-deficient cells, mouse, patient, patients, relapsed, solid tumor, therapeutic, tumor
Author NameAffiliation
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoFred Hutchinson Cancer Research Center
Raphael GottardoFred Hutchinson Cancer Research Center
Margaret Juliana McElrathClinical Research Division, Fred Hutchinson Cancer Research Center
Margaret Juliana McElrathFred Hutchinson Cancer Research Center
Margaret Juliana McElrathUniversity of Washington School of Medicine
Derek L StirewaltClinical Research Division, Fred Hutchinson Cancer Research Center
Derek L StirewaltUniversity of Washington School of Medicine
Aesha VakilFred Hutchinson Cancer Research Center
Aesha VakilClinical Research Division, Fred Hutchinson Cancer Research Center
  • 1 - 11

Datasets

Release 1.2